RT Journal Article
T1 Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study
A1 Ocio, Enrique M.
A1 Montes-Gaisan, Carmen
A1 Bustamante, Gabriela
A1 Garzon, Sebastian
A1 Gonzalez, Esther
A1 Perez, Ernesto
A1 Sirvent, Maialen
A1 Arguinano, Jose Maria
A1 Gonzalez, Yolanda
A1 Rios, Rafael
A1 de Miguel, Dunia
A1 Grande, Marta
A1 Fernandez, Alonso
A1 Naves, Andrea
A1 Rosinol, Laura
K1 Multiple myeloma
K1 Relapsed
K1 refractory multiple myeloma
K1 Treatment
K1 Sociodemographic characteristics
K1 Real word data
K1 Randomized controlled-trials
K1 Bortezomib
K1 Dexamethasone
K1 Lenalidomide
K1 Efficacy
K1 Therapy
K1 Phase-2
K1 Safety
K1 Burden
AB The characteristics of patients with RRMM in the real-world setting often differ from those enrolled in clinical trials, challenging therapeutic decisions in day-to-day practice. We retrospectively analyzed the sociodemographic and clinical characteristics of RRMM patients treated in routine clinical practice and their influence on the prescribing patterns in this setting. Treatment patterns among 276 RRMM patients from multiple hospitals were highly heterogeneous. The prescribed regimen was primarily influenced by the number of previous lines and the presence of osteopenia and extramedullary plasmacytomas. Our results rise awareness on the heterogeneity of the therapeutic landscape of RRMM in the real-world and highlight the complexity of therapeutic decision making in this population. Introduction: Treatment of relapsed and/or refractory multiple myeloma (RRMM) should be established based on multiple factors, including previous treatment and the sociodemographic/clinical characteristics of the patients. However, patients enrolled in randomized-controlled trials often do not mirror the scenario encountered in real-world practice, thus challenging therapeutic decisions in day-to-day practice. Patients and methods: This observational, cross-sectional, multicenter study aimed to investigate the sociodemographic and clinical characteristics of patients with RRMM treated in routine practice in Spain and their influence on treatment regimens. Results: The study included 276 RRMM patients (median age 69 years; no gender predominance). Seventy-four percent of patients had CRAB features at the time of study inclusion, 65.9% bone lesions, 28.7% high-risk cytogenetics, and 27.0% were at ISS stage III; 65.1% were retired and lived in urban areas (75.7%) with their relatives (85.8%); 28.7% had some dependence degree. Patients had experienced their last relapse in a median of 1.61 months before enrollment and had received a median of 2 treatment lines (range 1-10). Second-and third-line therapies were mostly based on immunomodulatory drugs, followed by proteasome inhibitors (PIs), whereas monoclonal antibodies prevailed in later treatment lines. The presence of extramedullary plasmacytomas, the absence of osteopenia, and being in the second or third treatment line (vs. later lines) significantly increased the odds of receiving PIs. Conclusions: RRMM treatment in the real-world setting is highly heterogeneous and is pr imar ily influenced by the number of previous lines. The consideration of patients' clinical and sociodemographic characteristics may support clinicians in making therapeutic decisions.
PB Cig media group, lp
SN 2152-2650
YR 2022
FD 2022-03-29
LK https://hdl.handle.net/10668/25106
UL https://hdl.handle.net/10668/25106
LA en
DS RISalud
RD Apr 6, 2025